RLAY — Relay Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $1.12bn
- $462.18m
- $10.01m
- 44
- 15
- 94
- 50
Annual income statement for Relay Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 82.7 | 3.03 | 1.38 | 25.5 | 10 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 138 | 368 | 301 | 399 | 382 |
| Operating Profit | -55.8 | -365 | -299 | -373 | -372 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -52.4 | -364 | -291 | -342 | -338 |
| Net Income After Taxes | -52.4 | -364 | -291 | -342 | -338 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -52.4 | -364 | -291 | -342 | -338 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -230 | -364 | -291 | -342 | -338 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.56 | -2.53 | -2.59 | -2.79 | -2.36 |